Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind study assigns about 40 participants with early Alzheimer's disease to receive either high-frequency transcranial random noise stimulation (tRNS) or sham stimulation for 14 days. Participants undergo baseline and post-treatment cognitive assessments plus EEG to explore neural changes. Stimulation uses a 4×1 electrode montage with a central anode delivering 1.5 mA at 100–640 Hz, and surrounding electrodes delivering a quarter of that current; sham mimics ramping without ongoing current. All participants are evaluated for eligibility, receive standard care, and are followed under blinded conditions to isolate the effect of tRNS on cognitive and behavioral symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.
* Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia
* CDR score ≤ 2
* Subject under treatment by IAChE for at least 3 months.
* psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months

Exclusion Criteria:

* NPI ≥ 4
* CDR \> 2
* Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).
* History of head injury,stroke,or other neurologic disease.
* Organic brain defects on T1 or T2 images.
* History of seizures or unexplained loss of consciousness.
* Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.
* Family history of medication refractory epilepsy.
* History of substance abuse within the last 6 months.

Where it's running

• Anhui Medical University, Hefei, Anhui 230032
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Kai Wang, PhD
• Email: wangkai1964@126.com
• Phone: +86-0551-62922263

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

• Test of amyloid-targeting medicines in healthy people and adults with Alzheimer’s

  This trial tests the safety and tolerability of amyloid-targeting drugs, plus a placebo, in healthy adults and in people with Alzheimer’s disease to see if the drugs can reduce brain amyloid plaques.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Anaheim, California and 18 other locations · NCT07787169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.